Kevin Starr is chairman of Decibel Therapeutics, a co-founder and partner of Third Rock Ventures, and a proven leader with more than 25 years of experience building and operating leading biotechnology companies.

In his role at Third Rock, Kevin focuses on the formation, development and business strategy of the firm’s portfolio companies, actively identifying and evaluating new investments. He has helped successfully raise $1.3 billion through the firm’s three funds. Kevin assumes active leadership roles in Third Rock portfolio companies, functioning as chief executive officer through the first 12-18 months after launch. In addition to Decibel, Kevin has been instrumental in launching and building a number of portfolio companies, including Afferent Pharmaceuticals, Agios Pharmaceuticals, Global Blood Therapeutics, MyoKardia, PanOptica, SAGE Therapeutics and Zafgen Pharmaceuticals.

Prior to Third Rock, Kevin served as chief operating officer and chief financial officer at Millennium Pharmaceuticals, where he helped raise billions of dollars in capital through strategic alliances and public financing and drove the company’s growth through organic expansion and mergers and acquisitions. Earlier in his career, he served in various executive roles at Biogen and Digital Equipment Corporation. Kevin holds an M.S. in corporate finance from Boston College and a B.A. in mathematics and business from Colby College. He is currently a board member of Alnylam Pharmaceuticals.

Steven Holtzman joined Decibel as president and chief executive officer in 2016. Steve brings more than 30 years of strategic, operational and leadership experience in the biotechnology industry. Prior to Decibel, he served as executive vice president, corporate development at Biogen, Inc., where he created and led the program leadership and management group through eight new drug approvals. He also led the business development and M&A group through successful completion of numerous transactions.

Prior to Biogen, Steve served as the founder, chief executive officer and chair of the board of directors of Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company. He was also an early leader and the chief business officer of Millennium Pharmaceuticals (now Takeda Oncology), a pioneer in large scale genetics and genomics, and was a founder, member of the board and the executive vice president of DNX Corporation, the first transgenic animal company. Steve is a member of the boards of directors of Visterra, Humatics, The Sync Project and Molecular Partners. In the not-for-profit arena, Steve is currently a trustee of the Berklee College of Music and previously served as the vice chairman of the board of trustees of the Hastings Center for Ethics and the Life Sciences. From 1996 to 2001, he served as a Presidential appointee to the U.S. National Bioethics Advisory Commission.

Steve received his B.A. in philosophy from Michigan State University and his B.Phil. graduate degree in philosophy from Corpus Christi College, Oxford University, which he attended as a Rhodes Scholar.

Craig Muir joined Third Rock Ventures in 2007 and has more than 25 years of technology development, implementation and application experience across the biotechnology and pharmaceutical industries. He leads the identification and integration of drug discovery and development technology platforms for companies across Third Rock’s portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes to scientific diligence for investment opportunities. Craig has been instrumental in expanding Third Rock’s San Francisco presence to increase access to innovative technologies and support the firm’s West Coast companies. Craig also assumes leadership roles in Third Rock portfolio companies, serving as interim chief technology or information officer through the first 12-18 months after launch.

Prior to Third Rock, Craig served as senior vice president of technical operations for Codon Devices. Before that, he spent 12 years at Millennium Pharmaceuticals as vice president of platform technology where his teams were instrumental in raising $1.8 billion from pharmaceutical partners. Earlier in his career, Craig served in a number of technology development and scientific roles at Genentech, Tularik and the University of Vermont.

Craig received his B.S. in animal physiology at the University of California, Davis and is a pioneer in the fields of laboratory automation and technology in biotech and pharmaceutical applications. Craig serves on the scientific advisory board of the Bigelow Laboratory for Ocean Sciences.

Jens Eckstein is president of SR One, the corporate venture capital arm of GlaxoSmithKline. He joined SR One from TVM Capital where he was last a venture partner, entrepreneur-in-residence and appointed CEO and president of SelectX Pharmaceuticals. Prior to that, he was a general partner in TVM’s Boston life sciences practice where he focused on earlier-stage investments. Jens was the founder of Akikoa Pharmaceuticals, a biotechnology start-up company focusing on hearing loss, and North Haven Systems, a life science IT company. Prior to joining TVM Capital, he led drug discovery programs at Enanta Pharmaceuticals, Inc. and Mitotix, Inc.

Jens is currently chairman of the board of directors of Thrasos Therapeutics, and a director at Palleon Therapeutics, Decibel Therapeutics, ZappRx, Gladius Pharmaceuticals and BioHealth Innovation (BHI). He was previously a member of the board of directors for Alios Biosciences, CoNCERT Pharmaceuticals, Enanta Pharmaceuticals, SelectX Pharmaceuticals, Rapid Micro Biosystems, Anchor Therapeutics, and an advisor and board observer to Sirtris Pharmaceuticals.

He is the author of multiple scientific publications and holds several issued and pending patents. As a Kauffman Fellow and angel investor Jens enjoys mentoring young entrepreneurs.

Jeff joined SAGE as CEO in 2013 and has more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, particularly in the CNS field. Before joining the SAGE team, Jeff served as president of the Regenerative Medicine Division of Shire plc and previously as senior vice president of research and development, pharmaceuticals at Shire. Prior to Shire, he served as the executive vice president of ISIS Pharmaceuticals, as the chief medical officer and executive vice president of Forest Laboratories, Inc. and in senior-level positions at Upjohn Laboratories. Jeff founded AVAX Technologies, where he served as CEO and president, and SCEPTOR Industries, where he served as chairman, president and chief technology officer. Earlier in his career, he served as independent director at Cara Therapeutics, Inc. and director of AVAX Technologies. He has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts, and has received numerous awards.

Jeff received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard and then served as chief resident in psychopharmacology at McLean Hospital, Harvard Medical School.

Dr. George Scangos assumed the position of chief executive officer of Vir Biotechnology, Inc., a company investing in cures, treatments, and preventions for challenging viral and bacterial diseases, including those caused by drug-resistant bacteria and emerging pathogens, in 2017. He served as chief executive officer of Biogen from 2010 and 2016 has more than 20 years of experience in the pharmaceutical and healthcare industries. Prior to Biogen, George served as the president and chief executive officer of Exelixis, Inc., a drug discovery and development company, where he continues to serve as a board member. Prior to Exelixis, he was president of Bayer Biotechnology and was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer’s biological products. George served as a professor of biology at Johns Hopkins University for six years, where he is still an adjunct professor.

George is currently chairman of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), a member of the board of trustees of the Boston Museum of Science and the Biomedical Science Careers Program, a member of the National Board of Visitors of the University of California, Davis School of Medicine, and a member of the board of Exelis. He also serves on the board of directors of Agilent Technologies, Inc. George previously served as executive chairman of Anadys Pharmaceuticals, Inc., the chair of the California Healthcare Institute and was a member of the board of the Global Alliance for TB Drug Development.

George holds a B.A. in biology from Cornell University and a Ph.D. in microbiology from the University of Massachusetts. He was a Jane Coffin Childs Postdoctoral Fellow in the laboratory of Frank Ruddle at Yale University.

Dr. Troyen Brennan is executive vice president and chief medical officer of CVS Health. In this role, Troy oversees the development of CVS Health’s clinical and medical affairs and health care strategy, as well as the company’s CVS MinuteClinic and Accordant Health Care business. Prior to CVS Health, Troy was chief medical officer of Aetna Inc., where he was responsible for clinical policies and Aetna's full range of clinical operations, disease management programs and patient management services. A leading authority in public health, Troy served as president and chief executive officer of Brigham and Women's Physicians Organization and as professor of medicine, law and public health at Harvard Medical School and Harvard School of Public Health.

Troy graduated with a B.S. from Southern Methodist University and received his M.A. from Oxford University, which he attended as a Rhodes Scholar. He received his M.D. and M.P.H. from Yale Medical School and his J.D. from Yale Law School. He completed his internship and residency in internal medicine at Massachusetts General Hospital and is currently a member of the Institute of Medicine of the National Academy of Sciences.

Roger Brown assumed the presidency of Berklee College of Music in 2004. During his tenure the college has created the world’s largest online music education system and expanded its global reach to attract students from 105 countries. Under his leadership scholarship support has grown from $9 million to $44 million. An accomplished entrepreneur, Brown cofounded Bright Horizons Family Solutions (NYSE: BFAM) in 1986 with his wife Linda Mason, now the largest worldwide provider of worksite childcare and early education, where he served as chief executive officer until January 2002. Bright Horizons has been named as one of the best companies to work for in America by Fortune magazine numerous times, employs 28,000 people, serves more than 80,000 families and has a market cap in excess of $4B.

Prior to that, he was co-director of the Save the Children relief and development effort in Sudan, and he worked on the border of Thailand with Cambodian refugees for CARE and UNICEF, both with Mason. Brown and Mason coauthored the book Rice, Rivalry, and Politics, which examines the management of emergency relief efforts. Brown also served as a management consultant for Bain and Company, a global management-consulting firm. Brown was one of the founders of the Bright Horizons Foundation for Children, which aids nonprofit agencies that work with at-risk children in communities where Bright Horizons employees live and work. He also cofounded Horizons for Homeless Children, which serves the needs of homeless children throughout the Boston area.

Brown is an active member of the Bright Horizons Family Solutions board of trustees and the Boston Public School Arts Advisory Board. He is a Phi Beta Kappa graduate of Davidson College with a B.A. in physics and earned his M.B.A. from Yale University.